NO331874B1 - 4-[2(aminometyl)-1,3-tiazol-4-yl]-2,6-di(tert-butyl)fenol, anvendelse som medikamenter samt anvendelse for behandling av sykdom. - Google Patents
4-[2(aminometyl)-1,3-tiazol-4-yl]-2,6-di(tert-butyl)fenol, anvendelse som medikamenter samt anvendelse for behandling av sykdom. Download PDFInfo
- Publication number
- NO331874B1 NO331874B1 NO20021689A NO20021689A NO331874B1 NO 331874 B1 NO331874 B1 NO 331874B1 NO 20021689 A NO20021689 A NO 20021689A NO 20021689 A NO20021689 A NO 20021689A NO 331874 B1 NO331874 B1 NO 331874B1
- Authority
- NO
- Norway
- Prior art keywords
- disease
- alkyl
- residue
- treatment
- disorders
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 201000010099 disease Diseases 0.000 title claims abstract description 9
- HAQOEWGSBVQDHB-UHFFFAOYSA-N 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-ditert-butylphenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N=C(CN)SC=2)=C1 HAQOEWGSBVQDHB-UHFFFAOYSA-N 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 11
- 208000002193 Pain Diseases 0.000 claims abstract description 11
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 9
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 8
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 6
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 5
- 208000035475 disorder Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 206010027599 migraine Diseases 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 208000032841 Bulimia Diseases 0.000 claims description 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 4
- 206010012335 Dependence Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 230000003542 behavioural effect Effects 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 4
- 231100000614 poison Toxicity 0.000 claims description 4
- 239000003440 toxic substance Substances 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 abstract description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 14
- 230000003859 lipid peroxidation Effects 0.000 abstract description 11
- 108010052164 Sodium Channels Proteins 0.000 abstract description 7
- 102000018674 Sodium Channels Human genes 0.000 abstract description 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 206010015037 epilepsy Diseases 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 102000010909 Monoamine Oxidase Human genes 0.000 abstract 2
- 108010062431 Monoamine oxidase Proteins 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 239000004305 biphenyl Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 210000003710 cerebral cortex Anatomy 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- -1 hydroxy, amino Chemical group 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- CCMLIFHRMDXEBM-UHFFFAOYSA-N 2-phenyl-1,3-thiazol-4-ol Chemical class OC1=CSC(C=2C=CC=CC=2)=N1 CCMLIFHRMDXEBM-UHFFFAOYSA-N 0.000 description 3
- ISNYUQWBWALXEY-UHFFFAOYSA-N Batrachotoxin Natural products C=1CC2(C3=CCC4C5(C)CCC(C4)(O)OC53C(O)C3)OCCN(C)CC32C=1C(C)OC(=O)C=1C(C)=CNC=1C ISNYUQWBWALXEY-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 125000003884 phenylalkyl group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- ISNYUQWBWALXEY-OMIQOYQYSA-N tsg6xhx09r Chemical compound O([C@@H](C)C=1[C@@]23CN(C)CCO[C@]3(C3=CC[C@H]4[C@]5(C)CC[C@@](C4)(O)O[C@@]53[C@H](O)C2)CC=1)C(=O)C=1C(C)=CNC=1C ISNYUQWBWALXEY-OMIQOYQYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000022306 Cerebral injury Diseases 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SFWZZSXCWQTORH-UHFFFAOYSA-N 1-methyl-2-phenylindole Chemical compound C=1C2=CC=CC=C2N(C)C=1C1=CC=CC=C1 SFWZZSXCWQTORH-UHFFFAOYSA-N 0.000 description 1
- NPNLTHPVLNUJEV-UHFFFAOYSA-N 2,2,4,4-tetramethylpentan-3-ylbenzene Chemical class CC(C)(C)C(C(C)(C)C)C1=CC=CC=C1 NPNLTHPVLNUJEV-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FZTBAQBBLSYHJZ-UHFFFAOYSA-N 2-phenyl-1,3-oxazol-4-ol Chemical class OC1=COC(C=2C=CC=CC=2)=N1 FZTBAQBBLSYHJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000002485 Adiposis dolorosa Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- FVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- HQYMUNCIMNFLDT-UHFFFAOYSA-N benzyl n-(2-amino-2-oxoethyl)carbamate Chemical compound NC(=O)CNC(=O)OCC1=CC=CC=C1 HQYMUNCIMNFLDT-UHFFFAOYSA-N 0.000 description 1
- DXJGOYKYERENGH-UHFFFAOYSA-N benzyl n-[[4-(3,5-ditert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl]carbamate Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N=C(CNC(=O)OCC=3C=CC=CC=3)SC=2)=C1 DXJGOYKYERENGH-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000002071 phenylalkoxy group Chemical group 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000002795 scorpion venom Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VXMJEMJQRVMGNS-UHFFFAOYSA-N tert-butyl n-[2-(methylamino)acetyl]carbamate Chemical compound CNCC(=O)NC(=O)OC(C)(C)C VXMJEMJQRVMGNS-UHFFFAOYSA-N 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950010357 tetrodotoxin Drugs 0.000 description 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- FVECELJHCSPHKY-JLSHOZRYSA-N veratridine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@@]2(O)O[C@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-JLSHOZRYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
Abstract
Foreliggende oppfinnelse angår forbindelser med den generelle formel (I) som kan anvendes for fremstilling av et medikament for hemning av monoaminoksydaser (MAO) og/eller for lipid peroksydasjon og/eller for å virke som modulatorer av natriumkanaler. Det resulterende medikament er spesielt for anvendelse for behandling av Parkinsons sykdom, senil demens, AIzheimers sykdom, Huntingtons chorea, amyotrofisk lateral sklerose, schizofreni, depresjon, psykoser, smerte og epilepsi. De nye forbindelsene har den generelle formel (I) hvor Het er en 5-leddet heterocyklisk gruppe omfattende 2 heteroatomer og er slik at den generelle formel (I) svarer utelukkende til en.av subformlene (l)1, (l)2, (l)a og (l)4> hvor A representerer spesielt en substituert fenyl- eller bifenylrest, B representerer spesielt H eller en alkylrest, X representerer spesielt NH eller S, Y representerer O eller S, n er et helt tall fra O til 6, R1 og R2 representerer, uavhengig av hverandre, spesielt restene valgt fra de følgende: hydrogen eller en alkyl- eller cykloalkylrest; og Q representerer NR46R47 eller OR48, hvor R46 og R47 representerer spesielt restene valgt fra de følgende: hydrogen og en alkyl-, cykloalkyl-, alkynyl-, cyanoalkyl- alkoksykarbonyl-, aralkoksykarbonyl- eller (cykloalkyl)oksykarbonyl-rest og R48 representerer hydrogen eller en alkyl-, alkynyl- eller cyanoalkynyl-rest.
Description
Foreliggende oppfinnelse angår 4-[2(aminometyl)-1,3-tiazol-4-yl]-2,6-di(tert-butyl)fenol, eller et salt av en slik forbindelse, denne forbindelse som medikament samt denne forbindelse for behandling av lidelser i det sentrale eller perifere nervesystem, schizofreni, depresjoner, psykoser, hukommelseslidelser og humourlidelser, adferdsforstyrrelser, bulimi og anoreksi, auto-immune og virale sykdommer, avhengighet av toksiske substanser.
I betraktning av den potensielle rollen til MAO og ROS (" reaktive oksygentypef', for begynnelsen av lipid peroksydasjon) i fysiopatologi, kan forbindelsen ifølge oppfinnelsen gi fordelaktige eller gunstige effekter ved behandling av patologier hvor disse enzymer og/eller disse radikaltyper er involvert. Spesielt: • lidelser i det sentrale eller perifere nervesystem så som for eksempel nevrologiske sykdommer, hvor Parkinson's sykdom, cerebrale eller ryggmarg- traumer, cerebralt infarkt, subaraknoidal blødning, epilepsi, aldring, senil demens, Alzheimers sykdom, Huntington's chorea, amyotrofisk lateralsklerose, perifere nevropatier og smerte spesielt kan nevnes; • schizofreni, depresjoner, psykoser; • forstyrrelser i hukommelse og humør; • patologier så som for eksempel migrene; • adferdsforstyrrelser, bulimi og anoreksi; • auto-immune og virale sykdommer så som for eksempel lupus, AIDS, parasittiske og virale infeksjoner, diabetes og dens komplikasjoner,
multippel sklerose.
• avhengighet av toksiske substanser; • proliferative og inflammatoriske patologier; • og mer generelt alle patologienekarakterisert veden for høy produksjon av ROS og/eller deltagelse av MAO.
Ved alle disse patologier eksisterer eksperimentelle bevis som demonstrerer involveringen av ROS { Free Radic. Biol. Med. (1996) 20, 675-705; Antioxid. Health. Dis. (1997) 4 (Handbook of Synthetic Antioxidants), 1-52) så vel som involveringen av MAO (Goodman & Gilman's: The pharmacological basis of therapeutics, 9. ed., 1995, 431-519).
Fordelen ved en kombinasjon av de hemmende aktivitetene til MAO og hemning av lipid peroksydasjon er for eksempel godt illustrert ved Parkinson's sykdom. Denne patologien erkarakterisert vedtap av dopaminerge neuroner i den nigrostriatale bane hvor årsaken til dette til dels vil være assosiert med oksyderende stress på grunn av ROS. Det exogene dopamin fra L Dopa blir anvendt i terapeutiske midler for å opprettholde tilstrekkelige nivåer av dopamin. MAO-inhibitorer blir også anvendt med L Dopa for å unngå dens metabolske nedbrytning, men virker ikke på ROS. Forbindelser som virker både på MAO og ROS vil derfor ha en viss fordel.
Videre er karakteren til modulatoren av natriumkanalene meget anvendelig for terapeutiske indikasjoner så som:
behandling eller forebygging av smerte og spesielt:
post-operativ smerte,
migrene,
nevropatisk smerte så som trigeminusnevralgi, post-herpetisk smerte, diabetiske nevropatier, glossofaryngeal nevralgi, sekundære radikulopatier og nevropatier forbundet med metastasiske infiltreringer, adiposis dolorosa og smerte forbundet med brannsår,
sentral smerte som et resultat av vaskulære cerebrale skader,
thalamiske lesjoner og multippel sklerose og
kronisk inflammatorisk smerte eller smerte knyttet til kreft; behandling av epilepsi;
behandling av lidelser relatert til nevrodegenerasjon og spesielt:
vaskulære cerebrale skader,
cerebralt traume og
nevrodegenerative sykdommer så som Alzheimer's sykdom,
Parkinson's sykdom og amyotrofisk lateralsklerose;
behandling av bipolare lidelser og irritert kolon-syndrom.
De konkrete fordeler ved tilstedeværelse av forbindelsen ifølge oppfinnelsen ved minst én av disse aktiviteter vil derfor være klare fra det ovenstående.
Europeisk patentsøknad EP 432 740 beskriver derivater av hydroksyfenyltiazoler, som kan anvendes ved behandling av inflammatoriske sykdommer, spesielt revmatiske sykdommer. Disse derivater av hydroksyfenyltiazoler viser egenskapene at de fanger opp frie radikaler og er inhibitorer av metabolismen av arakidonsyre (de hemmer lipoksygenase og cyklooksygenase).
Andre derivater av hydroksyfenyltiazoler eller hydroksyfenyloksazoler er beskrevet i PCT patentsøknad WO 99/09829. Disse har analgetiske egenskaper.
Et visst antall derivater av imidazoler med nære eller identiske strukturer til forbindelsen ifølge oppfinnelsen har videre vært beskrevet av søkeren i PCT patentsøknad WO 99/64401 som agonister eller antagonister for somatostatin. Imidlertid har nevnte derivater av imidazoler terapeutiske egenskaper på områder forskjellig fra de angitt ovenfor (undertrykking av veksthormonet og behandling av akromegali, behandling av tilbakekomst av stenose, hemning av sekresjon av mavesyre og forebygging av gastro-intestinal blødning spesielt).
Videre er forbindelsene med den generelle formel (A1)
hvor
R1 representerer aryl, heteroaryl, aralkyl eller cykloalkyl eventuelt substituert med én til tre substituenter uavhengig valgt fra et halogenatom, CF3, CN, OH, alkyl eller alkoksy, S02R9 hvor R9 representerer NH2eller NHCH3;
X representerer NR2, hvor R2 representerer H eller alkyl;
Y representerer N eller CR3;
Z representerer CR3 eller N;
imidlertid forutsatt at Y og Z ikke begge er CR3 eller N samtidig;
R3 representerer H, alkyl, halogen, hydroksyalkyl eller fenyl eventuelt substituert med 1 til 3 substituenter valgt fra H, CF3, CN, S02NH2, OH, alkyl eller alkoksy;
m representerer 0,1 eller 2;
R4 representerer H eller alkyl;
når Z representerer CR3, da kan R3 og R4 også sammen representere -(CH2)ni- hvor n1 et helt tall fra 2 til 4 eller R2 og R4 kan også sammen representere -(CH2)n2- hvor n2 et helt tall fra 2 til 4;
R5 og R6 uavhengig representerer H, alkyl, alkoksy, aryl eller aralkyl;
NR5R6 kan også sammen representere (spesielt):
- en eventuelt substituert 2-(1,2,3,4-tetrahydrokinolyl)-rest,
- en rest
hvor R7 representerer én av fenyl-, benzyl- eller fenetyl-rester hvor fenylringen kan være substituert;
- en rest
hvor p er et helt tall fra 1 til 3,
W er N og R8 representerer H, CF3, én av fenyl-, pyridyl- eller pyrimidinyl-restene er eventuelt substituert én til to ganger med rester valgt fra halogen, OH, alkyl eller alkoksy, eller
W er CH og R8 representerer fenyl eventuelt substituert eller aralkyl eventuelt substituert på arylgruppen;
beskrevet i PCT patentsøknad WO 96/16040 som partielle agonister eller antagonister av dopamin subreseptorer i hjernen eller som prodrugformer av slike partielle agonister eller antagonister. Disse forbindelsene ville derfor ha anvendelige egenskaper for diagnose og behandling av affekt-forstyrrelser så som schizofreni og depresjon så vel som visse bevegelsesforstyrrelser så som Parkinson's sykdom.
Det er også beskrevet i PCT patentsøknad WO 98/27108 at visse amider med den generelle formel (A2)
hvor:
R1 representerer spesielt alkyl, eventuelt substituert fenyl eller eventuelt substituert heterocyklisk aryl; R2 representerer H eller fenylalkyl; R4 representerer H, kinolyl, 3-4-metylendioksyfenyl eller én av fenyl-eller pyridylrestene eventuelt substituert med en rest eller rester valgt spesielt fra alkyl, alkoksy, alkyltio, eventuelt beskyttet hydroksy, amino, alkylamino, dialkylamino; R5 representerer H eller imidazolyl, fenyl, nitrofenyl, fenylalkyl eller også en -CO-N(R7)(R8) rest, hvor R7 og R8 uavhengig representerer H, fenyl, fenylalkyl, alkyl eller alkoksy; eller R4 og R5 i kombinasjon danner en gruppe med formelen -CH=CH-CH=CH-;
Y er en fenylenrest substituert med en fenyl-, fenoksy- eller fenylalkoksy-rest eller en gruppe med formelen -CH(R3)-, hvor R3 representerer H eller en rest med formelen -(CH2)n-R6, hvor R6 representerer eventuelt beskyttet hydroksy, acyl, karboksy, acylamino, alkoksy, fenylalkoksy, alkyltio, eventuelt substituert fenyl, eventuelt substituert pyridyl, pyrazinyl, pyrimidinyl, furyl, imidazolyl, naftyl, N-alkylindolyl eller 3,4-metylendioksyfenyl og n er et helt tall fra 0 til 3;
R2 og R3 sammen med karbonatomene som bærer dem kan danne en fenylgruppe;
X representerer S eller NR9;
R9 representerer H, alkyl eller cykloalkyl eller også en benzylrest eventuelt substituert én gang på dens fenyldel med H, alkyl eller alkoksy;
er inhibitorer av NO-syntaser og kan anvendes for å behandle sykdommer som omfatter spesielt kardiovaskulær eller cerebral ischemi, hjerneblødning, lidelser i sentralnervesystemet, Alzheimer's sykdom, multippel sklerose, diabetes, hepatitt, migrene, revmatoid artritt og osteoporose.
På et annet område har søkeren selv tidligere beskrevet i PCT patentsøknad WO 98/58934 derivater av amidiner som har evnen til å hemme NO-syntaser og/eller lipid peroksydasjon.
Søkeren har nå uventet oppdaget at 4-[2(aminometyl)-1,3-tiazol-4-yl]-2,6-di(tert-butyl)fenol, har minst én av de tre egenskaper valgt fra de følgende egenskaper (og ofte selv to av disse tre egenskaper, til og med noen ganger alle tre samtidig): - MAO-hemmende egenskaper;
- lipid peroksydasjon hemmende egenskaper; og
- egenskaper for modulering av natriumkanalene.
Disse fordelaktige egenskapene gir fordelen at de åpner for en rekke anvendelser av slike forbindelser, spesielt ved behandling av nevrodegenerative sykdommer og spesielt de angitt tidligere, med smerte eller epilepsi.
Oppfinnelsen angår spesielt forbindelsekarakterisert vedat produktet er
4-[2(aminometyl)-1,3-tiazol-4-yl]-2,6-di(tert-butyl)fenol,
eller et salt av en slik forbindelse.
Videre angår oppfinnelsen forbindelsen over som medikament.
Oppfinnelsen angår videre forbindelsen over for behandling av lidelser i det sentrale eller perifere nervesystem, schizofreni, depresjoner, psykoser, hukommelseslidelser og humourlidelser, adferdsforstyrrelser, bulimi og anoreksi, auto-immune og virale sykdommer, avhengighet av toksiske substanser.
Spesielt angår oppfinnelsen forbindelsene over for behandling av Parkinson's sykdom, senil demens, Alzheimers sykdom, Huntington's chorea, amyotrofisk lateralsklerose, schizofreni, depresjoner, psykoser, migrene eller smerter og særlig Huntington's chorea.
Forbindelsen over har minst to av aktivitetene nevnt ovenfor. Spesielt vil den ha både en antagonistaktivitet vis-å-vis natriumkanalene og en oppfangende aktivitet på ROS.
Dette gjør forbindelsen ifølge oppfinnelsen anvendelig ved behandling av sykdommene nevnt tidligere så som å bindes til MAO, til lipid peroksydasjon og til natriumkanalene.
Oppfinnelsen angår videre, som medikamenter, forbindelsen ifølge foreliggende oppfinnelse eller deres farmasøytisk akseptable salter.
Spesielt kan forbindelsen ifølge oppfinnelsen anvendes for fremstilling av et medikament ment for å behandle én av de følgende lidelser eller én av de følgende sykdommer: Parkinson's sykdom, senil demens, Alzheimer's sykdom, Huntington's chorea, amyotrofisk lateralsklerose, schizofreni, depresjoner, psykoser, migrene eller smerter og spesielt nevropatiske smerter.
Med farmasøytisk akseptabelt salt, menes spesielt addisjonssaltene med uorganiske syrer så som hydroklorid, hydrobromid, hydrojodid, sulfat, fosfat, difosfat og nitrat eller med organiske syrer så som acetat, maleat, fumarat, tartrat, succinat, citrat, laktat, metansulfonat, p-toluensulfonat, pamoat og stearat. Også omfattet på området for foreliggende oppfinnelse, når de kan anvendes, er saltene dannet fra baser så som natrium- eller kaliumhydroksyd. For andre eksempler på farmasøytisk akseptable salter, kan det refereres til "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
Det farmasøytiske preparatet kan være i form av et fast stoff, for eksempel pulvere, granuler, tabletter, gelatinkapsler, liposomer eller suppositorier. Passende faste bærere kan for eksempel være kalsiumfosfat, magnesiumstearat, talk, sukkere, laktose, dekstrin, stivelse, gelatin, cellulose, metylcellulose, natriumkarboksymetylcellulose, polyvinylpyrrolidin og voks.
De farmasøytiske preparater inneholdende en forbindelse ifølge foreliggende oppfinnelse kan også presenteres i flytende form, for eksempel løsninger, emulsjoner, suspensjoner eller siruper. Passende flytende bærere kan for eksempel være vann, organiske løsningsmidler så som glycerol eller glykoler, og også blandinger derav, i varierende forhold, i vann.
Administreringen av et medikament ifølge oppfinnelsen kan utføres topisk, oralt, parenteralt, ved intramuskulær injeksjon, etc.
Administreringsdosen ment for et medikament ifølge oppfinnelsen omfatter mellom 0,1 mg til 10 g i henhold til typen aktiv forbindelse anvendt.
I henhold til oppfinnelsen kan forbindelsene med den generelle formel (I) fremstilles ved prosessene beskrevet nedenfor.
Fremstilling avforbindelsene og eksempler ifølgeforeliggende o<pp>finnelse:
EKSEMPLER
Referanseeksem<p>el : benzyl{4-[3,5-di(tert-butyl)-4-hydroksyfenyl]-1,3-tiazol-2-yl}metylkarbamat: Forbindelsen blir produsert i henhold til en eksperimentell protokoll beskrevet i patentsøknad WO 98/58934 (se fremstilling av mellomprodukter 26,1 og 26,2), ved anvendelse avZ-Gly-NH2istedenfor N-Boc-sarcosinamid. Den forventede forbindelse blir oppnådd i form av en blekgul olje i et utbytte på 99%.
MH+ = 453,20
Eksempel: 4-[2-(aminometyl)-1,3-tiazol-4-yl]-2,6-di(tert-butyl)fenol:
0,1 ml av en 40% løsning av kaliumhydroksyd blir satt dråpevis til en løsning av 0,106 g (1,1 mmol) av forbindelsen i referanseeksemplet over i 10 ml metanol. Etter omrøring natten over under tilbakeløp blir reaksjonsblandingen konsentrert under vakuum og residuet blir fortynnet med diklormetan og vasket med en 1 N løsning av HCI og deretter med 50 ml av en mettet løsning av NaCI. Den organiske fasen blir separert og tørket over magnesiumsulfat, filtrert og konsentrert under vakuum. Det forventede produkt blir oppnådd etter kromatografi på en silikakolonne (elueringsmiddel: 5% etanol i diklormetan) i form av et brunt skum i et utbytte på 76%.
MH+ = 319,29.
Farmakologisk undersøkelse av produktene ifølge foreliggende oppfinnelse
Undersøkelse av effektene på lipid peroksydasjon av hjernebarken til en rotte
Den hemmende aktiviteten av produktene ifølge foreliggende oppfinnelse blir bestemt ved å måle deres effekter på graden av lipid peroksydasjon, bestemt ved konsentrasjonen av malondialdehyd (MDA). MDA produsert av peroksydasjon av umettede fettsyrer er en god indikasjon på lipid peroksydasjon (H Esterbauerog KH Cheeseman, Meth. Enzymol. (1990) 186: 407-421). Sprague Dawley hannrotter som veier 200 til 250 g (Charles River) ble avlivet ved halshugging. Hjernebarken blir fjernet og deretter homogenisert ved anvendelse av Thomas potter i en 20 mM Tris-HCI buffer, pH = 7,4. Homogenatet blir sentrifugert to ganger ved 50000 g i 10 minutter ved 4°C. Pelleten blir lagret ved -80°C. På forsøksdagen blir pelleten resuspendert i en konsentrasjon på 1 g/15 ml og sentrifugert ved 515 g i 10 minutter ved 4° C. Supernatanten blir anvendt umiddelbart for å bestemme lipid peroksydasjon. Homogenatet av rottens hjernebark (500 ul) blir inkubert ved 37°C i 15 minutter i nærvær av forbindelsene som skal testes eller av løsningsmidlet (10 ul). Lipid peroksydasjon-reaksjon blir initiert ved tilsetning av 50 ul FeCfeved 1 mM, EDTA ved 1 mM og askorbinsyre ved 4 mM. Etter inkubering i 30 minutter ved 37°C blir reaksjonen stanset ved tilsetning av 50 ul av en løsning av hydroksylert di-tert-butyl-toluen (BHT, 0,2 %). MDA blir kvantifisert ved anvendelse av en kolorimetrisk test, ved reaksjon av et kromogent reagens (R), N-metyl-2-fenylindol (650 ul) med 200 ul av homogenatet i 1 time ved 45°C. Kondensering av et MDA-molekyl med to molekyler av reagens R gir en stabil kromofor maksimal absorbans bølgelengde som er lik 586 nm. (Caldwell et al. European J. Pharmacol. (1995) 285, 203-206). Forbindelsene ifølge Referanseeksemplet og Eksemplet beskrevet ovenfor oppviser en IC50lavere enn 10 uM.
Bindingstest på de cerebrale natriumkanaler i cortex fra rotte
Testen består i måling av interaksjonen av forbindelsene vis-å-vis bindingen av tritiert batrachotoksin på de spenningsavhengige natriumkanaler i henhold til protokollen beskrevet av Brown ( J. Neurosci. (1986), 6, 2064-2070).
Preparering av homogenater av hjernebark fra rotte
Hjernebark fra Sprague-Dawley rotter som veier 230-250 g (Charles River, Frankrike) fjernes, veies og homogeniseres ved anvendelse av en Potter homogenisator utstyrt med et teflonstempel (10 slag) i 10 volumer av isolerings-buffer hvor sammensetningen er som følger (sukrose 0,32 M; K2HPO45 mM; pH 7,4). Homogenatet blir underkastet en første sentrifugering ved 1000 g i 10 minutter. Supernatanten blir fjernet og sentrifugert ved 20000 g i 15 minutter. Pelleten blir tatt opp i isoleringsbufferen og sentrifugert ved 20000 g i 15 minutter. Pelleten oppnådd blir resuspendert i inkuberingsbuffer (HEPES 50 mM; KCI 5,4 mM; MgS040,8 mM; glukose 5,5 mM; cholinklorid 130 mM pH 7,4) og deretter aliquot-fordelt og lagret ved -80°C inntil forsøksdagen. Den endelige protein-konsentrasjon er mellom 4 og 8 mg/ml. Forsøket med proteiner blir utført ved anvendelse av et sett markedsført av BioRad (Frankrike).
Måling av bindingen av tritiert batrachotoksin
Bindingsreaksjonen blir utført ved inkubering i 1 time 30 minutter ved 25°C av 100 ul av homogenat fra rotte-cortex inneholdende 75 ug proteiner med 100 ul [<3>H] batrachotoksin-A 20-alfa-benzoat (37,5 Ci/mmol, NEN) ved 5 nM (endelig konsentrasjon), 200 ul tetrodotoksin ved 1 uM (endelig konsentrasjon) og skorpiongift ved 40 ug/ml (endelig konsentrasjon) og 100 ul av inkuberingsbuffer alene eller i nærvær av produktene som skal testes i forskjellige konsentrasjoner. Den ikke-spesifikke bindingen blir bestemt i nærvær av 300 uM veratridin og verdien av denne ikke-spesifikke bindingen blir subtrahert fra alle de andre verdiene. Prøvene blir deretter filtrert ved anvendelse av en Brandel (Gaithersburg, Maryland, USA) ved anvendelse av Unifilter GF/C plater preinkubert med 0,1 % polyetylenimin (20 pl/brønn) og skyllet to ganger med 2 ml filtreringsbuffer (HEPES 5 mM; CaCb 1,8 mM; MgS040,8 mM; cholinklorid 130 mM; BSA 0,01 %; pH 7,4). Etter å ha tilsatt 20 ul Mikroscint 0<®>, blir radioaktiviteten tellet ved anvendelse av en væske-scintillasjonsteller (Topcount, Packard). Målingen blir utført in duplo. Resultatene er uttrykt som % av den spesifikke bindingen av tritiert batrachotoksin i forhold til kontrollen.
Resultater
Forbindelsen i Eksemplet, ovenfor viser en IC50lavere enn eller lik 1 uM. Videre viser forbindelsen i Referanseeksemplet beskrevet ovenfor, en IC50lavere enn eller lik 3,5 uM.
Claims (5)
1. Forbindelsekarakterisert vedat produktet er
^^(aminometyO-l.a-tiazoM-yl^.e-di^ert-butyOfenol,
eller et salt av en slik forbindelse.
2. Forbindelse ifølge krav 1 som medikament.
3. Forbindelse ifølge krav 1 for behandling av lidelser i det sentrale eller perifere nervesystem, schizofreni, depresjoner, psykoser, hukommelseslidelser og humourlidelser, adferdsforstyrrelser, bulimi og anoreksi, auto-immune og virale sykdommer, avhengighet av toksiske substanser.
4. Forbindelse ifølge krav 3 for behandling av Parkinson's sykdom, senil demens, Alzheimers sykdom, Huntington's chorea, amyotrofisk lateralsklerose, schizofreni, depresjoner, psykoser, migrene eller smerter.
5. Forbindelse ifølge krav 4 for behandling av Huntington's chorea.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9912643A FR2799461B1 (fr) | 1999-10-11 | 1999-10-11 | Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments |
FR0010151A FR2812546B1 (fr) | 2000-08-01 | 2000-08-01 | Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments |
FR0011169 | 2000-09-01 | ||
PCT/FR2000/002805 WO2001026656A2 (fr) | 1999-10-11 | 2000-10-10 | Derives d'heterocycles a 5 chainons et leur application comme inhibiteurs de monoamine oxydase |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20021689D0 NO20021689D0 (no) | 2002-04-10 |
NO20021689L NO20021689L (no) | 2002-05-30 |
NO331874B1 true NO331874B1 (no) | 2012-04-23 |
Family
ID=27248695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20021689A NO331874B1 (no) | 1999-10-11 | 2002-04-10 | 4-[2(aminometyl)-1,3-tiazol-4-yl]-2,6-di(tert-butyl)fenol, anvendelse som medikamenter samt anvendelse for behandling av sykdom. |
Country Status (27)
Country | Link |
---|---|
US (4) | US20070021390A1 (no) |
EP (3) | EP1223933B1 (no) |
JP (1) | JP4972263B2 (no) |
KR (2) | KR20070068491A (no) |
CN (1) | CN100488506C (no) |
AR (1) | AR029006A1 (no) |
AT (2) | ATE338547T1 (no) |
AU (1) | AU783129B2 (no) |
BR (1) | BR0014649A (no) |
CA (1) | CA2388505C (no) |
CY (1) | CY1106237T1 (no) |
CZ (1) | CZ304331B6 (no) |
DE (1) | DE60030574T2 (no) |
DK (2) | DK1589007T3 (no) |
ES (2) | ES2544856T3 (no) |
HK (1) | HK1049957B (no) |
HU (1) | HU228254B1 (no) |
IL (3) | IL148896A0 (no) |
MX (1) | MXPA02003665A (no) |
MY (1) | MY145388A (no) |
NO (1) | NO331874B1 (no) |
NZ (2) | NZ518304A (no) |
PL (1) | PL215580B1 (no) |
PT (2) | PT1589007E (no) |
RU (1) | RU2271355C2 (no) |
TW (2) | TWI292316B (no) |
WO (1) | WO2001026656A2 (no) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2823208B1 (fr) * | 2001-04-10 | 2004-03-19 | Sod Conseils Rech Applic | Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments |
TWI292316B (en) * | 1999-10-11 | 2008-01-11 | Sod Conseils Rech Applic | Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof |
US7291641B2 (en) * | 1999-10-11 | 2007-11-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
FR2818978B1 (fr) * | 2000-12-28 | 2003-02-28 | Sod Conseils Rech Applic | Modulateurs de canaux sodiques derives de 2-piperidylimidazoles |
TWI248438B (en) * | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
FR2825926A1 (fr) * | 2001-06-14 | 2002-12-20 | Sod Conseils Rech Applic | Derives d'imidazoles modulant les canaux sodiques |
HU228783B1 (en) | 2001-07-26 | 2013-05-28 | Greenearth Cleaning | Dry cleaning apparatus and method capable of utilizing a siloxane solvent |
US6815555B2 (en) | 2001-09-26 | 2004-11-09 | Theravance, Inc. | Substituted phenol compounds useful for anesthesia and sedation |
JP2005512975A (ja) | 2001-10-25 | 2005-05-12 | アストラゼネカ アクチボラグ | 抗菌薬として有用なイソキサゾリン誘導体 |
WO2003048140A1 (fr) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Compose azole et utilisation medicinale de celui-ci |
FR2835254B1 (fr) * | 2002-01-25 | 2006-04-07 | Sod Conseils Rech Applic | Derives de thiazoles dans le traitement de maladies neurologiques |
FR2842808B1 (fr) * | 2002-07-25 | 2004-09-10 | Sod Conseils Rech Applic | Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques |
KR20050033070A (ko) | 2002-08-09 | 2005-04-08 | 아스트라제네카 에이비이 | 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸 |
US7074809B2 (en) | 2002-08-09 | 2006-07-11 | Astrazeneca Ab | Compounds |
WO2004014370A2 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
WO2004071448A2 (en) * | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases |
MXPA05010945A (es) * | 2003-04-09 | 2005-11-25 | Japan Tobacco Inc | Compuesto pentaciclico heteroaromatico y uso medicinal del mismo. |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
TWI256952B (en) * | 2003-08-27 | 2006-06-21 | Sk Corp | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders |
EP1533295A1 (en) * | 2003-11-24 | 2005-05-25 | Newron Pharmaceuticals S.p.A. | Cyclopentyl Derivatives |
US20070185217A1 (en) | 2003-12-23 | 2007-08-09 | Abraxis Bioscience, Inc. | Propofol analogs, process for their preparation, and methods of use |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
CA2571002A1 (en) * | 2004-06-18 | 2006-01-05 | Chiron Corporation | N-(1-(1-benzyl-4-phenyl-1h-imidazol-2-yl)-2,2-dimethylpropyl)benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer |
JP5197014B2 (ja) * | 2004-12-10 | 2013-05-15 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ヒストンデアセチラーゼ(hdac)阻害剤としての複素環誘導体 |
EP1841426B1 (en) * | 2005-01-19 | 2011-04-27 | Merck Sharp & Dohme Corp. | Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease |
FR2888116A1 (fr) * | 2005-07-08 | 2007-01-12 | Sod Conseils Rech Applic | Derives de thiazoles pour traiter les dyskinesies |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
BRPI0806264A2 (pt) | 2007-01-05 | 2011-08-30 | Novartis Ag | derivados ciclizados como inibidores de eg-5 |
TW200848417A (en) * | 2007-02-22 | 2008-12-16 | Organon Nv | Indole derivatives |
MX2009009234A (es) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | Uso nuevo de inhibidores de ciclasa de glutaminilo. |
EP2114867B1 (en) * | 2007-03-05 | 2012-12-12 | F. Hoffmann-La Roche AG | Aminoamides as orexin antagonists |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
EP2105163B1 (de) * | 2008-03-28 | 2011-06-08 | MagForce Nanotechnologies AG | Magnetwechselfeld-Applikationsvorrichtung zur Aufheizung von magnetischen oder magnetisierbaren Substanzen in biologischem Gewebe |
US20110190356A1 (en) * | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
GB0822486D0 (en) * | 2008-12-10 | 2009-01-14 | Univ Liverpool | Compounds for use in the treatment of pain |
KR101220182B1 (ko) | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법 |
ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
RU2506082C2 (ru) * | 2011-05-24 | 2014-02-10 | Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова | Антигипотоническое средство |
CA2850925C (en) * | 2011-10-26 | 2017-01-10 | Pfizer Limited | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators |
WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
WO2013131018A1 (en) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
CN105764507B (zh) | 2013-07-12 | 2019-07-19 | 诺普生物科学有限责任公司 | 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平 |
ES2871556T3 (es) | 2013-08-13 | 2021-10-29 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de la urticaria crónica |
ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
WO2022015782A1 (en) * | 2020-07-15 | 2022-01-20 | Board Of Trustees Of Michigan State University | Compositions and related methods for closed-loop recycling of polyesters |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR4231E (fr) | 1905-08-25 | Francisque Voland | Disposition nouvelle de métier à tisser, en vue de l'obtention d'un tissu biaisé | |
US1743083A (en) * | 1928-02-03 | 1930-01-07 | Winthrop Chem Co | Catechol thiazoles and process of making the same |
FR2132632A1 (en) * | 1971-04-07 | 1972-11-24 | Berlin Chemie Veb | Prepn of 2-aminomethyl imidazole derivs - hypotensives mao inhibitors anticonvulsant s, antiphlogistics, choleretics and ant |
US4123529A (en) | 1976-04-23 | 1978-10-31 | Lilly Industries Limited | Phenylpiperazine derivatives |
DE2702714A1 (de) | 1977-01-24 | 1978-07-27 | Lek Tovarna Farmacevtskih | Verfahren zur herstellung von phenothiazin-derivaten |
US4348404A (en) * | 1980-07-21 | 1982-09-07 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines |
US4372964A (en) * | 1980-10-30 | 1983-02-08 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-1H-imidazole-2-methanols |
JPS62132871A (ja) * | 1985-12-03 | 1987-06-16 | Yamanouchi Pharmaceut Co Ltd | 新規チアゾ−ル誘導体 |
JP3003148B2 (ja) * | 1989-01-05 | 2000-01-24 | 藤沢薬品工業株式会社 | チアゾール化合物、その製造法およびそれを含有する医薬組成物 |
CA2012716A1 (en) * | 1989-03-22 | 1990-09-22 | Akito Tanaka | Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same |
DE3941438A1 (de) * | 1989-12-15 | 1991-06-20 | Hoechst Ag | Neue 2-substituierte 4-(3-alkyl-5-tert.-butyl-4-hydroxy-phenyl)-thiazole, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung |
GB9204958D0 (en) * | 1992-03-06 | 1992-04-22 | Fujisawa Pharmaceutical Co | Thiazole derivatives |
MX9700041A (es) * | 1994-06-29 | 1997-04-30 | Smithkline Beecham Corp | Antagonistas de receptor de vitronectina. |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
CN1088062C (zh) * | 1994-11-23 | 2002-07-24 | 纽罗根公司 | 某些4-氨基甲基-2-取代的咪唑衍生物2-氨基甲基-4-取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体 |
FR2727969B1 (fr) * | 1994-12-09 | 1997-01-17 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
DE69722258T2 (de) * | 1996-10-07 | 2004-03-18 | Eli Lilly And Co., Indianapolis | Neue verbindungen nutlich als neuroschützende mittel |
EP0946587A2 (en) | 1996-12-16 | 1999-10-06 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds |
US6335445B1 (en) * | 1997-03-24 | 2002-01-01 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
FR2764889B1 (fr) * | 1997-06-20 | 2000-09-01 | Sod Conseils Rech Applic | Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
AU9034798A (en) | 1997-08-28 | 1999-03-16 | Eli Lilly And Company | Method for treating pain |
CN1281442A (zh) * | 1997-10-06 | 2001-01-24 | 伊莱利利公司 | 用作神经保护剂的新颖化合物 |
DE69921124T2 (de) * | 1998-06-12 | 2005-11-10 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden |
RU2233841C2 (ru) * | 1998-06-12 | 2004-08-10 | Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас | Бета-карболиновые соединения, фармацевтические композиции на их основе и способы связывания, достижения агонистического/антагонистического эффекта |
HUP0104708A3 (en) * | 1998-12-31 | 2004-05-28 | Sod Conseils Rech Applic | Prenyl transferase inhibitors and medicaments containing them |
WO2000057877A1 (en) * | 1999-03-26 | 2000-10-05 | Euro-Celtique S.A. | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
TWI292316B (en) * | 1999-10-11 | 2008-01-11 | Sod Conseils Rech Applic | Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof |
ES2275619T3 (es) * | 2000-12-20 | 2007-06-16 | Astrazeneca Ab | Quetiapina para el tratamiento de discinesia en pacientes no psicoticos. |
TWI248438B (en) | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
-
2000
- 2000-10-09 TW TW093132951A patent/TWI292316B/zh not_active IP Right Cessation
- 2000-10-09 TW TW089121109A patent/TWI283577B/zh not_active IP Right Cessation
- 2000-10-10 PT PT50767490T patent/PT1589007E/pt unknown
- 2000-10-10 BR BR0014649-8A patent/BR0014649A/pt not_active IP Right Cessation
- 2000-10-10 IL IL14889600A patent/IL148896A0/xx active IP Right Grant
- 2000-10-10 PT PT00967988T patent/PT1223933E/pt unknown
- 2000-10-10 MY MYPI20004725A patent/MY145388A/en unknown
- 2000-10-10 DK DK05076749.0T patent/DK1589007T3/en active
- 2000-10-10 DE DE60030574T patent/DE60030574T2/de not_active Expired - Lifetime
- 2000-10-10 CA CA2388505A patent/CA2388505C/fr not_active Expired - Fee Related
- 2000-10-10 MX MXPA02003665A patent/MXPA02003665A/es active IP Right Grant
- 2000-10-10 KR KR1020077013941A patent/KR20070068491A/ko active IP Right Grant
- 2000-10-10 KR KR1020027004578A patent/KR100731698B1/ko not_active IP Right Cessation
- 2000-10-10 EP EP00967988A patent/EP1223933B1/fr not_active Expired - Lifetime
- 2000-10-10 ES ES05076749.0T patent/ES2544856T3/es not_active Expired - Lifetime
- 2000-10-10 NZ NZ518304A patent/NZ518304A/en not_active IP Right Cessation
- 2000-10-10 WO PCT/FR2000/002805 patent/WO2001026656A2/fr active Application Filing
- 2000-10-10 ES ES00967988T patent/ES2270873T3/es not_active Expired - Lifetime
- 2000-10-10 CN CNB008158479A patent/CN100488506C/zh not_active Expired - Fee Related
- 2000-10-10 AU AU77965/00A patent/AU783129B2/en not_active Ceased
- 2000-10-10 EP EP05076749.0A patent/EP1589007B1/fr not_active Expired - Lifetime
- 2000-10-10 EP EP02076763A patent/EP1228760B1/fr not_active Expired - Lifetime
- 2000-10-10 AT AT00967988T patent/ATE338547T1/de active
- 2000-10-10 AT AT02076763T patent/ATE522213T1/de not_active IP Right Cessation
- 2000-10-10 PL PL355147A patent/PL215580B1/pl not_active IP Right Cessation
- 2000-10-10 CZ CZ2002-1292A patent/CZ304331B6/cs not_active IP Right Cessation
- 2000-10-10 HU HU0203841A patent/HU228254B1/hu not_active IP Right Cessation
- 2000-10-10 RU RU2002112227/15A patent/RU2271355C2/ru not_active IP Right Cessation
- 2000-10-10 DK DK00967988T patent/DK1223933T3/da active
- 2000-10-10 JP JP2001529718A patent/JP4972263B2/ja not_active Expired - Fee Related
- 2000-10-10 NZ NZ533429A patent/NZ533429A/en not_active IP Right Cessation
- 2000-10-11 AR ARP000105353A patent/AR029006A1/es active IP Right Grant
-
2002
- 2002-03-26 IL IL148896A patent/IL148896A/en not_active IP Right Cessation
- 2002-04-10 NO NO20021689A patent/NO331874B1/no not_active IP Right Cessation
-
2003
- 2003-03-06 HK HK03101645.4A patent/HK1049957B/zh not_active IP Right Cessation
-
2005
- 2005-10-24 US US11/256,901 patent/US20070021390A1/en not_active Abandoned
-
2006
- 2006-11-08 CY CY20061101600T patent/CY1106237T1/el unknown
-
2007
- 2007-02-20 US US11/708,531 patent/US20070179153A1/en not_active Abandoned
- 2007-08-08 IL IL185118A patent/IL185118A0/en not_active IP Right Cessation
- 2007-12-11 US US12/001,439 patent/US7956075B2/en not_active Expired - Fee Related
-
2011
- 2011-03-21 US US13/053,092 patent/US8288560B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO331874B1 (no) | 4-[2(aminometyl)-1,3-tiazol-4-yl]-2,6-di(tert-butyl)fenol, anvendelse som medikamenter samt anvendelse for behandling av sykdom. | |
KR101779272B1 (ko) | 키나제 억제제로서의 신규 벤즈이미다졸 유도체 | |
Perez et al. | Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds | |
US20070054900A1 (en) | 4-Phenlthiazole and 4-phenylimidizole derivatives and their use as medicaments for the treatment of neurodegenerative diseases, pain and epilepsy | |
US10058540B2 (en) | 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors | |
WO2014190199A1 (en) | Compounds for treatment of drug resistant and persistent tuberculosis | |
AU2017365123B2 (en) | Heteroarylphenoxy benzamide kappa opioid ligands | |
EP2318382A1 (fr) | NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
EP2310366A2 (fr) | NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET | |
US20020028809A1 (en) | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | |
AU781064B2 (en) | Di-substituted iminoheterocyclic compounds | |
FR2933982A1 (fr) | Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
WO2017147312A1 (en) | Combination therapies for treatment of spinal muscular atrophy | |
Hamdani et al. | Densely substituted piperidines as a new class of elastase inhibitors: Synthesis and molecular modeling studies | |
WO2009119167A1 (ja) | 抗rnaウイルス作用を有するアニリン誘導体 | |
EP2643307B1 (fr) | Derives de nitrobenzothiazoles et leur utilisation pour le traitment de la tubercolose | |
AU782771B2 (en) | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholine receptors activators | |
CN108239081B (zh) | 一种抑制rock的化合物及其应用 | |
AU2009335931B2 (en) | Arylcyclopropylacetamide derivatives useful as glucokinase activators | |
AU2018278284A1 (en) | Carboxylic acid derivatives of pyridoquinazolines useful as protein kinase inhibitors | |
US20080108683A1 (en) | 4-phenylthiazole and 4-phenylimidizole derivatives and their use as medicaments for the treatment of neurodegenerative diseases, pain and epilepsy | |
Chasák et al. | Expanding the squaramide library as mycobacterial ATP synthase inhibitors: Innovative synthetic pathway and biological evaluation | |
TWI386392B (zh) | 一種可作為過氧小體增生活化受體調控劑的磺酸基取代雙環化合物 | |
Henise | Development of cell-active irreversible inhibitors of the human centrosomal kinase Nek2 | |
AU2008278824A1 (en) | Compounds for treating Duchenne muscular dystrophy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |